Listen to Article

On 1 October, Reuters reported some COVID War news, good and bad.

First, the bad news. Actually, it's not really "news" to report that the highly-touted COVID vaccines, once hyped to the public as the miracle cure that would vanquish the deadly virus once and for all—see "VACCINE WILL SAVE THE DAY" (28 Apr 2020)—have exhibited significant loss of effectiveness over time. 

Numerous Trends Journal articles have addressed this; see, for example:

But now Reuters tells of a new study which finds that, at least in the case of the Pfizer-BioNTech shots, levels of vaccine-induced antibodies which have the power to neutralize the original strain of COVID-19 drop, by a factor of 10, within 7 mos. of the original dose. 

Furthermore, in half the patients studied, neutralizing antibodies which are effective against variants—such as Delta, Beta and Mu—were undetectable 6 mos. after the second dose.

The researchers point out that such neutralizing antibodies are not the immune system's only means of defense against the virus, but they are "critically important" in protecting against infection. 

TREND FORECAST: Totally absent Presstitutes reporting and government mandates is the hard fact that the COVID Jab was sold to the public as having a 96 percent efficacy rate: Two shots and it’s over. Never COVID again... safe for the rest of your life.

That lie has now changed. So, what's the conclusion? Booster shots will be needed 6 to 7 mos. after the initial dose to enhance protection against COVID-19 and its variants. Quelle surprise! Of course, this is good news if you're making, selling or otherwise promoting booster shots. 

Remember, the Drug Lords' plan is for new variants to continue to appear, necessitating more shots, at least annually, in perpetuity, on the model of flu shots; see "MORE COVID JABS, MORE BIG BUCKS FOR DRUG LORDS" (28 Sep 2021).

And Now, Some Good News?

The same Reuters story reports that pharmaceutical giant Merck & Co. has entered the fray with a pill to fight COVID. 

The company announced on 1 October that its experimental, orally-administered antiviral drug for COVID-19, Molnupiravir, tested on mild to moderately infected patients who had severe risk factors, cut patients' hospitalization and death rates in half.

The article quotes Amesh Adalja, of the Johns Hopkins Center for Health Security: "An oral antiviral that can impact hospitalization risk to such a degree would be game changing." 

The drug operates by introducing errors into the virus's genetic code. It would be the first anti-COVID-19 drug in pill form.

TRENDPOST: Merck intends to seek Emergency Use Authorization from U.S. Food & Drug Administration; this was the route taken to rapidly bring the COVID vaccines into distribution. The procedure allows the FDA to recommend that a drug or vaccine, which has gone through only a few months of trials, be released to the general public; it usually takes several years to determine potential long-term health consequences. See "FDA APPROVES U.S. VACCINE" (15 Dec 2020).

Support the Trends Journal with these great products

  1. RICHARD ALLEN 12 months ago

    Just my opinion, but to me…for all the pharmaceutical companies out their making anti covid this and that, the Genie is out of the bottle and won’t be going back in…ever. They will seek EUA for any and all perceived immediate threats to public health, and their govt masters whom they provide lucrative stock options too, will grant them.

  2. lowbornhighbrow 12 months ago

    Ingenious of Merck. Don’t get your name dragged through the mud from vile vials. Then patent the patented truly “safe and effective” treatment. But at a massive mark-up.

  3. Richard McKenzie 12 months ago

    What’s in the pill? Ivermectin?

    • Val Gentry 12 months ago

      I am wondering the same thing. I would definitely want to read/ see what is in the pill before ingesting. I don’t have a lot of faith in Big Pharma anymore.

  4. Kieran Simpson 12 months ago

    Richard said it all in his question eh.

Leave a reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

©2022 The Trends Journal

Log in with your credentials

Forgot your details?